OncoHost Presents New Research Revealing Biological Drivers of TKI Sensitivity in Metastatic Renal Cell Carcinoma at ESMO 2026

BINYAMINA, Israel and CARY, N.C., Oct. 26, 2026 /PRNewswire/ -- OncoHost, a technology company transforming the approach to predictive precision diagnostics for improved patient outcomes, today announced new research that was presented at the European Society for Medical Oncology (ESMO)...

Read the full story at OncoHost via PR Newswire (opens in a new tab)

Headline and summary from OncoHost via PR Newswire; the full story is on the publisher's site. Nothing here is investment advice.